188 related articles for article (PubMed ID: 35664705)
1. Palmitoyl transferases act as potential regulators of tumor-infiltrating immune cells and glioma progression.
Tang F; Yang C; Li FP; Yu DH; Pan ZY; Wang ZF; Li ZQ
Mol Ther Nucleic Acids; 2022 Jun; 28():716-731. PubMed ID: 35664705
[TBL] [Abstract][Full Text] [Related]
2. Hypomethylation-induced prognostic marker zinc finger DHHC-type palmitoyltransferase 12 contributes to glioblastoma progression.
Lu F; Shen SH; Wu S; Zheng P; Lin K; Liao J; Jiang X; Zeng G; Wei D
Ann Transl Med; 2022 Mar; 10(6):334. PubMed ID: 35434031
[TBL] [Abstract][Full Text] [Related]
3. Palmitoyl transferases act as novel drug targets for pancreatic cancer.
Lin Z; Lv Z; Liu X; Huang K
J Transl Med; 2023 Apr; 21(1):249. PubMed ID: 37038141
[TBL] [Abstract][Full Text] [Related]
4. ZDHHC15 promotes glioma malignancy and acts as a novel prognostic biomarker for patients with glioma.
Liu ZY; Lan T; Tang F; He YZ; Liu JS; Yang JZ; Chen X; Wang ZF; Li ZQ
BMC Cancer; 2023 May; 23(1):420. PubMed ID: 37161425
[TBL] [Abstract][Full Text] [Related]
5. MSC-AS1 knockdown inhibits cell growth and temozolomide resistance by regulating miR-373-3p/CPEB4 axis in glioma through PI3K/Akt pathway.
Li C; Feng S; Chen L
Mol Cell Biochem; 2021 Feb; 476(2):699-713. PubMed ID: 33106913
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of circHIPK3 Facilitates Temozolomide Sensitivity in Glioma by Regulating Cellular Behaviors Through miR-524-5p/KIF2A-Mediated PI3K/AKT Pathway.
Yin H; Cui X
Cancer Biother Radiopharm; 2021 Sep; 36(7):556-567. PubMed ID: 32833501
[No Abstract] [Full Text] [Related]
7. Salvianolic acid A (Sal A) suppresses malignant progression of glioma and enhances temozolomide (TMZ) sensitivity via repressing transgelin-2 (TAGLN2) mediated phosphatidylinositol-3-kinase (PI3K) / protein kinase B (Akt) pathway.
Ye T; Chen R; Zhou Y; Zhang J; Zhang Z; Wei H; Xu Y; Wang Y; Zhang Y
Bioengineered; 2022 May; 13(5):11646-11655. PubMed ID: 35505656
[TBL] [Abstract][Full Text] [Related]
8. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
9. MiR-3116 sensitizes glioma cells to temozolomide by targeting FGFR1 and regulating the FGFR1/PI3K/AKT pathway.
Kong S; Cao Y; Li X; Li Z; Xin Y; Meng Y
J Cell Mol Med; 2020 Apr; 24(8):4677-4686. PubMed ID: 32181582
[TBL] [Abstract][Full Text] [Related]
10. BKM120 sensitizes C6 glioma cells to temozolomide via suppression of the PI3K/Akt/NF-κB/MGMT signaling pathway.
Li M; Liang RF; Wang X; Mao Q; Liu YH
Oncol Lett; 2017 Dec; 14(6):6597-6603. PubMed ID: 29151909
[TBL] [Abstract][Full Text] [Related]
11. Regulation of dendrite morphology and excitatory synapse formation by zDHHC15.
Shah BS; Shimell JJ; Bamji SX
J Cell Sci; 2019 Jul; 132(13):. PubMed ID: 31189538
[TBL] [Abstract][Full Text] [Related]
12. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
[TBL] [Abstract][Full Text] [Related]
13. Exosome-mediated transfer of MIF confers temozolomide resistance by regulating TIMP3/PI3K/AKT axis in gliomas.
Wei QT; Liu BY; Ji HY; Lan YF; Tang WH; Zhou J; Zhong XY; Lian CL; Huang QZ; Wang CY; Xu YM; Guo HB
Mol Ther Oncolytics; 2021 Sep; 22():114-128. PubMed ID: 34514093
[TBL] [Abstract][Full Text] [Related]
14. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment.
Lefranc F; Rynkowski M; DeWitte O; Kiss R
Adv Tech Stand Neurosurg; 2009; 34():3-35. PubMed ID: 19368079
[TBL] [Abstract][Full Text] [Related]
15. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
[TBL] [Abstract][Full Text] [Related]
16. KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment.
D'Alessandro G; Grimaldi A; Chece G; Porzia A; Esposito V; Santoro A; Salvati M; Mainiero F; Ragozzino D; Di Angelantonio S; Wulff H; Catalano M; Limatola C
Oncotarget; 2016 May; 7(21):30781-96. PubMed ID: 27096953
[TBL] [Abstract][Full Text] [Related]
17. Bioinformatics Analysis of the Prognostic and Biological Significance of ZDHHC-Protein Acyltransferases in Kidney Renal Clear Cell Carcinoma.
Liu Z; Liu C; Xiao M; Han Y; Zhang S; Xu B
Front Oncol; 2020; 10():565414. PubMed ID: 33364189
[TBL] [Abstract][Full Text] [Related]
18. Exosomal circ-HIPK3 Facilitates Tumor Progression and Temozolomide Resistance by Regulating miR-421/
Han C; Wang S; Wang H; Zhang J
Cancer Biother Radiopharm; 2021 Sep; 36(7):537-548. PubMed ID: 32644821
[No Abstract] [Full Text] [Related]
19. MicroRNA-144 represses gliomas progression and elevates susceptibility to Temozolomide by targeting CAV2 and FGF7.
Liu ZQ; Ren JJ; Zhao JL; Zang J; Long QF; Du JJ; Jia XT; Gu NB; Di ZL; Qian YH; Li SZ
Sci Rep; 2020 Mar; 10(1):4155. PubMed ID: 32139705
[TBL] [Abstract][Full Text] [Related]
20. Microarray analysis of circRNAs expression profile in gliomas reveals that circ_0037655 could promote glioma progression by regulating miR-214/PI3K signaling.
Qiao J; Liu M; Tian Q; Liu X
Life Sci; 2020 Mar; 245():117363. PubMed ID: 32001271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
